Paul E. Oberstein
About
Paul E. Oberstein is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Paul E. Oberstein has authored 70 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 18 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul E. Oberstein's work include Pancreatic and Hepatic Oncology Research (31 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cancer Genomics and Diagnostics (17 papers). Paul E. Oberstein is often cited by papers focused on Pancreatic and Hepatic Oncology Research (31 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cancer Genomics and Diagnostics (17 papers). Paul E. Oberstein collaborates with scholars based in United States, Spain and Switzerland. Paul E. Oberstein's co-authors include Kenneth P. Olive, Carmine F. Palermo, Stephen A. Sastra, Ian Tattersall, Dafydd Thomas, Maite G. Fernández‐Barrena, Jan Kitajewski, C. Benedikt Westphalen, Ben Z. Stanger and Andrew D. Rhim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.
In The Last Decade
Paul E. Oberstein
63 papers receiving 2.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Paul E. Oberstein United States | 14 | 2.2k | 934 | 745 | 625 | 388 | 70 | 2.8k | ||
| Tyler Saunders United States | 9 | 2.1k 1.0× | 962 1.0× | 804 1.1× | 437 0.7× | 344 0.9× | 9 | 2.7k | ||
| Daniel Öhlund Sweden | 17 | 1.3k 0.6× | 802 0.9× | 572 0.8× | 431 0.7× | 189 0.5× | 35 | 2.0k | ||
| Dafydd Thomas United States | 10 | 1.4k 0.6× | 693 0.7× | 438 0.6× | 507 0.8× | 287 0.7× | 15 | 1.9k | ||
| Carmine F. Palermo United States | 8 | 1.3k 0.6× | 629 0.7× | 405 0.5× | 417 0.7× | 228 0.6× | 17 | 1.7k | ||
| Todd T. Moore United States | 12 | 1.8k 0.8× | 686 0.7× | 373 0.5× | 1.4k 2.3× | 319 0.8× | 17 | 2.8k | ||
| Josep M. Piulats Spain | 30 | 1.5k 0.7× | 1.1k 1.2× | 448 0.6× | 894 1.4× | 316 0.8× | 162 | 3.2k | ||
| Irina Matei United States | 15 | 1.3k 0.6× | 1.4k 1.5× | 946 1.3× | 692 1.1× | 98 0.3× | 24 | 2.8k | ||
| Yuko Mataki Japan | 27 | 1.7k 0.8× | 820 0.9× | 664 0.9× | 532 0.9× | 685 1.8× | 117 | 2.7k | ||
| Abdel Hosein United States | 13 | 1.0k 0.5× | 1.5k 1.6× | 963 1.3× | 418 0.7× | 128 0.3× | 17 | 2.4k | ||
| Hiroyuki Shinchi Japan | 28 | 1.7k 0.8× | 680 0.7× | 490 0.7× | 642 1.0× | 753 1.9× | 105 | 2.7k |
Countries citing papers authored by Paul E. Oberstein
Since
Specialization
Citations
This map shows the geographic impact of Paul E. Oberstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Oberstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Oberstein more than expected).
Fields of papers citing papers by Paul E. Oberstein
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Paul E. Oberstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Oberstein. The network helps show where Paul E. Oberstein may publish in the future.
Co-authorship network of co-authors of Paul E. Oberstein
This figure shows the co-authorship network connecting the top 25 collaborators of Paul E. Oberstein. A scholar is included among the top collaborators of Paul E. Oberstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul E. Oberstein. Paul E. Oberstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wu, Feng, Soyoung Kwak, Chan Wang, et al.. (2025). Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. JAMA Oncology. 11(11). 1331–1331.
2.
Wang, Chan, Mykhaylo Usyk, Soyoung Kwak, et al.. (2025). Association of tumor microbiome with survival in resected early-stage PDAC. mSystems. 10(3). e0122924–e0122924.
3.
Saeed, Anwaar, Paul E. Oberstein, Dan G. Duda, et al.. (2025). S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncology. 21(11). 1325–1331.
4.
Spira, Alexander I., Kyriakos P. Papadopoulos, Daewon Kim, et al.. (2025). Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.. Journal of Clinical Oncology. 43(4_suppl). 724–724.
5.
Lakhani, Nehal J., Davide Melisi, Vivek Subbiah, et al.. (2025). MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors.. Journal of Clinical Oncology. 43(4_suppl).
6.
Oberstein, Paul E., et al.. (2025). Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions. Current Treatment Options in Oncology. 26(10). 841–865.
7.
Picozzi, Vincent J., Anna M. Varghese, Paul E. Oberstein, et al.. (2025). Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.. Journal of Clinical Oncology. 43(4_suppl). 673–673.
8.
Cohen, Deirdre Jill, Judith D. Goldberg, Lawrence P. Leichman, et al.. (2024). Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.. Journal of Clinical Oncology. 42(16_suppl). 4175–4175.
9.
Oberstein, Paul E., Andrea Wang‐Gillam, Anna M. Varghese, et al.. (2024). Precision Promise (PrP) Bayesian platform trial for metastatic pancreatic cancer (mPDAC): Results of the first experimental arm, SM-88 as second line therapy.. Journal of Clinical Oncology. 42(3_suppl). 675–675.
10.
Peng, Chengwei, Paul E. Oberstein, Charlene Thomas, et al.. (2024). Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network. 22(8). 521–527.
11.
Oberstein, Paul E., et al.. (2023). ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress).. Journal of Clinical Oncology. 41(4_suppl). TPS263–TPS263.
12.
Um, Caroline Y., Brandilyn A. Peters, Paul E. Oberstein, et al.. (2022). Grain, Gluten, and Dietary Fiber Intake Influence Gut Microbial Diversity: Data from the Food and Microbiome Longitudinal Investigation. Cancer Research Communications. 3(1). 43–53.
13.
Peters, Brandilyn A., Mykhaylo Usyk, Caroline Y. Um, et al.. (2022). Elevated Dietary Carbohydrate and Glycemic Intake Associate with an Altered Oral Microbial Ecosystem in Two Large U.S. Cohorts. Cancer Research Communications. 2(12). 1558–1568.
14.
Eng, Cathy, Emerson Y. Chen, Jane E. Rogers, et al.. (2021). Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice. 17(10). 607–614.
15.
Payen, Thomas, Paul E. Oberstein, Carmine F. Palermo, et al.. (2019). Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. Clinical Cancer Research. 26(6). 1297–1308.
16.
Hingorani, Sunil R., Lei Zheng, Andrea J. Bullock, et al.. (2017). HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology. 36(4). 359–366.
17.
Le, Dung T., Andrew H. Ko, Zev A. Wainberg, et al.. (2017). Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. Journal of Clinical Oncology. 35(4_suppl). 345–345.
18.
Manji, Gulam A., Kenneth P. Olive, Yvonne M. Saenger, & Paul E. Oberstein. (2017). Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research. 23(7). 1670–1678.
19.
Rhim, Andrew D., Paul E. Oberstein, Dafydd Thomas, et al.. (2014). Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell. 25(6). 735–747.
20.
Oberstein, Paul E., Barton Kenney, Saravanan Krishnamoorthy, Yanghee Woo, & Muhammad Wasif Saif. (2012). Metastatic Gastric Large Cell Neuroendocrine Carcinoma: A Case Report and Review of Literature. Clinical Colorectal Cancer. 11(3). 218–223.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tyler Saunders Breakdown of academic impact, for papers by Daniel Öhlund Breakdown of academic impact, for papers by Dafydd Thomas Breakdown of academic impact, for papers by Carmine F. Palermo Breakdown of academic impact, for papers by Todd T. Moore Breakdown of academic impact, for papers by Josep M. Piulats Breakdown of academic impact, for papers by Irina Matei Breakdown of academic impact, for papers by Yuko Mataki Breakdown of academic impact, for papers by Abdel Hosein Breakdown of academic impact, for papers by Hiroyuki Shinchi